Abelacimab

• Description:

  Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain. This interaction ensures FXI remains in its zymogen form, effectively inhibiting activation by FXIIa or thrombin. Such a mechanism underscores Abelacimab's potential application in thromboembolic disease research .

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Molecular Formula:

  ——

• Notes:

  Research use only, not for human use.

• Receptor:

  Others

• CAS Number:

  2098724-83-3